18552406. CONTROLLED RELEASE OF BACTERIOPHAGE TO TREAT IMPLANT INFECTIONS simplified abstract (The Board of Trustees of the Leland Stanford Junior University)
Contents
- 1 CONTROLLED RELEASE OF BACTERIOPHAGE TO TREAT IMPLANT INFECTIONS
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 CONTROLLED RELEASE OF BACTERIOPHAGE TO TREAT IMPLANT INFECTIONS - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Original Abstract Submitted
CONTROLLED RELEASE OF BACTERIOPHAGE TO TREAT IMPLANT INFECTIONS
Organization Name
The Board of Trustees of the Leland Stanford Junior University
Inventor(s)
Ovijit Chaudhuri of Stanford CA (US)
Paul L. Bollyky of Stanford CA (US)
Robert Manasherob of Stanford CA (US)
Yung-Hao Lin of Stanford CA (US)
Derek Amanatullah of Stanford CA (US)
CONTROLLED RELEASE OF BACTERIOPHAGE TO TREAT IMPLANT INFECTIONS - A simplified explanation of the abstract
This abstract first appeared for US patent application 18552406 titled 'CONTROLLED RELEASE OF BACTERIOPHAGE TO TREAT IMPLANT INFECTIONS
Simplified Explanation
The abstract describes a patent application for hydrogels containing bacteriophages for controlled release to treat bacterial infections.
- Hydrogels contain bacteriophages bonded within for sustained release.
- Engineered for controlled release of bacteriophages within the body.
- Methods provided for forming the hydrogels and treating bacterial infections.
Potential Applications
The technology can be applied in the medical field for treating bacterial infections in patients.
Problems Solved
This technology addresses the challenge of delivering bacteriophages in a controlled and sustained manner to effectively combat bacterial infections.
Benefits
The hydrogels offer a targeted and sustained release of bacteriophages, potentially improving treatment outcomes for bacterial infections.
Potential Commercial Applications
The hydrogels could be commercialized for use in medical settings for treating various bacterial infections.
Possible Prior Art
Prior art may include existing methods of delivering bacteriophages for treating bacterial infections, but the specific approach of covalently bonding them within hydrogels for controlled release may be novel.
Unanswered Questions
How does this technology compare to traditional antibiotic treatments for bacterial infections?
This article does not directly compare the effectiveness or drawbacks of this technology compared to traditional antibiotic treatments.
What are the potential long-term effects of using bacteriophages in hydrogels for treating bacterial infections?
The article does not address any potential long-term effects or considerations of using bacteriophages in hydrogels for treating bacterial infections.
Original Abstract Submitted
Provided herein are hydrogels that include a plurality of bacteriophages located within and covalently bonded to the hydrogel interior. The hydrogel is engineered to facilitate a controlled sustained release of the connected bacteriophages, e.g., to or within the body of a patient suffering from a bacterial infection. Also provided are methods for forming the provided hydrogels, and for using the hydrogels to treat a patient suffering from a bacterial infection.
